MedTrace Logo

Endocardial Mapping With the CoreMap EP Mapping System

NCT06529978 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 245

Last updated 2026-03-11

No results posted yet for this study

Summary

This is a global, multi-site, prospective, feasibility study.

Conditions

  • Persistent Atrial Fibrillation

Interventions

DEVICE

CoreMap EP Mapping System Map-Guided Ablation

Initial development and evaluation of a map-guided tailored ablation strategy and to demonstrate safety and chronic efficacy of the CoreMap EP Mapping System.

DEVICE

CoreMap EP Mapping System Mapping

Endocardial mapping to collect and analyze high fidelity endocardial EGMs in patients with persistent and long-standing persistent AF.

Sponsors & Collaborators

  • CoreMap Inc.

    lead INDUSTRY

Principal Investigators

  • Sarah Kalil · CoreMap Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-25
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Device
Yes

Countries

  • United States
  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06529978 on ClinicalTrials.gov